Clinical trials: Metastatic Liver Cancers
Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma
Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction
This phase I trial studies the best dose and side effects of tazemetostat in treating patients with solid tumors or B-cell lymphomas with liver dysfunction that have spread to other places in the body or cannot be removed by…
- Conditions
- Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma, Metastatic Malignant Solid Neoplasm, Stage III Hepatocellular Carcinoma AJCC v7
- Trial name
- NCT03217253
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Tazemetostat
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Colorectal Carcinoma
Neoadjuvant Recombinant Vaccinia Virus for Metastatic Colorectal Cancer With Liver Resection
This is a neoadjuvant Phase 2a, open-label trial in patients with metastatic colorectal carcinoma who are undergoing a complete resection of the metastatic colorectal tumors in their liver.
- Trial name
- NCT01329809
- Testing
- Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Jennerex Biotherapeutics
Colorectal Neoplasms, Neoplasm Metastasis
Health Economic Evaluation of Primovist-enhanced Liver MRI
Patients with a history of colorectal cancer and known or suspected liver metastases who are scheduled for contrast-enhanced tomographic imaging will be included in this study.
- Trial name
- NCT00764621
- Testing
- Primovist MRI, Extracellular contrast media (ECCM) MRI, Contrast-enhanced CT
- Where
- 44 sites in Austria, Germany and 7 more
- Volunteers
- 360 people
- Sponsor
- Bayer
Melanoma, Colon Cancer
Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer
Background: Exome sequencing can identify certain gene mutations in a person's tumor. This can then be used to create cancer treatments.
- Conditions
- Melanoma, Colon Cancer, Gastrointestinal Cancer, Genitourinary Cancer
- Trial name
- NCT03480152
- Testing
- National Cancer Institute (NCI)-4650, a messenger ribonucleic acid (mRNA)-based, Personalized Cancer Vaccine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Stage IV Melanoma
LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma
The purpose of this study is to determine if LC beads loaded with Doxorubicin are a safe and effective treatment for melanoma that has spread to the liver.
- Trial name
- DEBDOX (NCT01010984)
- Testing
- LC beads loaded with Doxorubicin
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Robert C. Martin
Colorectal Cancer Metastatic, Colorectal Cancer
TheraSphere® For Treatment of Metastases in Liver
To investigate whether the dose predicted by pre-therapy 99mTc MAA SPECT predicts the dose to the liver from the 90Y microspheres as assessed by post-therapy 90Y SPECT/CT or positron emission tomography (PET)/CT.
- Trial name
- NCT04517643
- Testing
- Therasphere Therapy
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Cancer, Melanoma
Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors
This is a pilot study designed to evaluate the cutaneous effect of systemic inhibition of the tyrosine kinase pathway in the presence or absence of solar simulated light exposure.
- Conditions
- Metastatic Cancer, Melanoma, Colon Cancer, Differentiated Thyroid Cancer
- Trial name
- NCT03176485
- Testing
- Solar Simulator
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Arizona
Liver Metastases, Metastases to Liver
China Metastatic Liver Cancer Clinical Registry Cohort Database
This study is led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close collaboration with multiple participating centers nationwide.
- Conditions
- Liver Metastases, Metastases to Liver, Liver Cancer, Neoplasms
- Trial name
- NCT07602504
- Testing
- Standard of Care for Metastatic Liver Cancer
- Where
- 3 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Anhui Provincial Hospital
Solid Tumor, Adult
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
This is a Phase 1 dose-finding study of FT538 in combination with monoclonal antibodies.
- Trial name
- NCT05069935
- Testing
- FT538, Cyclophosphamide, Fludarabine
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Fate Therapeutics
Carcinoma, Hepatocellular
Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma
The aim of this study is to compare the efficacy of sorafenib to 5-fluorouracil/mitomycin in HCC patients with pulmonary metastasis whose intrahepatic tumors has been controlled with locoregional therapies.
- Trial name
- NCT01171482
- Testing
- 5-FU, Mitomycin, sorafenib
- Where
- South Korea
- Volunteers
- 5 people
- Sponsor
- Seoul National University Hospital
Liver Cancer, Metastatic Cancer
Hepatic Arterial Infusion With Melphalan in Treating Patients With Unresectable Liver Cancer
RATIONALE: Heating melphalan to several degrees above body temperature and infusing it to the affected area directly around the tumor may kill more tumor cells.
- Trial name
- NCT00030082
- Testing
- isolated perfusion, melphalan
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignant Neoplasm, Colorectal Carcinoma Metastatic in the Liver
Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
This phase I trial studies the side effects and best dose of combination chemotherapy and bevacizumab, and to see how well they work with the NovoTTF-100L(P) system in treating participants with cancer that has come back or does…
- Conditions
- Advanced Malignant Neoplasm, Colorectal Carcinoma Metastatic in the Liver, Metastatic Malignant Neoplasm in the Liver, Refractory Malignant Neoplasm
- Trial name
- NCT03203525
- Testing
- Bevacizumab, Fluorouracil, Leucovorin
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer Metastatic, Liver Metastases
A Trial of Camrelizumab Combined With Microwave Ablation and Chemotherapy in the Treatment of Colorectal Cancer Liver Metastasis/Pulmonary Metastasis
Currently, comprehensive treatments for liver metastasis/pulmonary metastasis that cannot reach NED include systemic chemotherapy, interventional chemotherapy, molecular targeted therapy, immunotherapy, and local treatments…
- Conditions
- Colorectal Cancer Metastatic, Liver Metastases, Lung Metastases
- Trial name
- NCT04888806
- Testing
- Camrelizumab, ablation, chemotherapy
- Volunteers
- 37 people
- Sponsor
- Harbin Medical University
Colorectal Cancer With Non Resectable Hepatic Metastasis
Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study
Treatment of patients with colorectal cancer having liver metastases is currently based on systemic chemotherapy. Triple therapy with 5FU, oxaliplatin and irinotecan intravenously was effective in terms of response and secondary…
- Trial name
- NCT01839877
- Testing
- HIA DEBIRI + systemic FOLFOX
- Where
- 9 sites in France
- Volunteers
- 58 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Cancer
Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients
This Phase II study is conducted to assess the safety and efficacy of CPI-613 in patients with advanced and/or metastatic solid tumors for whom there there is no available therapy to provide clinical benefit or for those who have…
- Trial name
- NCT01832857
- Testing
- CPI-613
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Cornerstone Pharmaceuticals
Hepatocellular Carcinoma
Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC)
The prognosis for patients with metastatic or locally advanced hepatocellular carcinoma (HCC) is poor. The role of conventional systemic chemotherapy has been very limited because most chemotherapeutic agents are in-effective and…
- Trial name
- NCT00464919
- Testing
- Sorafenib, tegafur/uracil (UFUR®)
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- National Taiwan University Hospital
Colorectal Cancer Metastatic, Liver Metastasis Colon Cancer
COLLISION XL: Unresectable Colorectal Liver Metastases (3-5cm): Stereotactic Body Radiotherapy vs. Microwave Ablation
Multiple articles report that thermal ablation is a safe and effective treatment for unresectable colorectal liver metastases (CRLM) ≤3cm. However efficacy of thermal ablation decreases with increasing lesion size.
- Trial name
- COLLISION-XL (NCT04081168)
- Testing
- Stereotactic Body Radiotherapy, Microwave Ablation
- Where
- Netherlands
- Volunteers
- 68 people
- Sponsor
- Amsterdam UMC, location VUmc
Gastric Cancer Metastatic to Liver
Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Gastric Cancer Liver Metastasis (CASTLE-09)
The objective of this study is to evaluate the efficacy and safety of cryoablation combined with Tislelizumab plus Lenvatinib for patients with gastric cancer liver metastasis in the second-/third-Line setting.
- Trial name
- CASTLE-09 (NCT05893056)
- Testing
- Cryoablation, Tislelizumab, Lenvatinib
- Where
- 2 sites in China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma, Circulating Tumor Cell
Prognostic Value of Liver Cancer CTCs Isolated by a Novel Microfluidic Platform
This study aims to isolate CTCs in peripheral venous blood of liver cancer patients by inertial focusing principle-based microfluidic device, determine the relationship between the number of CTCs and patient prognosis and…
- Conditions
- Hepatocellular Carcinoma, Circulating Tumor Cell, Whole Genome Sequencing
- Trial name
- NCT05242237
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Colorectal Cancer Metastatic
INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastases
Nelitolimod is a classC toll-like receptor 9 (TLR9) agonist that binds to TLR9 receptors on myeloid-derived suppressor cells(MDSCs) and helps reshape the tumor microenvironment (TME) and promote antitumor immunity.
- Trial name
- NCT07172282
- Testing
- Nelitolimod
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Northwell Health
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.